E
Tharimmune, Inc. THAR
$1.18 -$0.075-6.00%
Recommendation
Sell
Prev Close
$1.18
Volume
65,031
Avg Vol (90D)
107,342
Market Cap
$2.48M
Dividend & Yield
--
52-Week Range
$1.14 - $6.98
P/E (TTM)
--
EPS (TTM)
-$9.89
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory ...
3/31/2025 - GuruFocus
Tharimmune announces FDA feedback on NDA path for TH104
3/31/2025 - The Fly
Tharimmune announces FDA feedback on TH104 NDA path
3/31/2025 - The Fly
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
3/31/2025 - Accesswire
Tharimmune (NASDAQ:THAR) Issues Quarterly Earnings Results
3/27/2025 - Ticker Report
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor ...
3/24/2025 - GuruFocus
Tharimmune announces preclinical results for oral antibody TH023
3/24/2025 - TipRanks Financial Blog
Tharimmune announces preclinical results for oral antibody TH023
3/24/2025 - The Fly
Tharimmune announce preclinical TH023 results
3/24/2025 - The Fly
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
3/24/2025 - Accesswire
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and ...
3/4/2025 - GuruFocus
Tharimmune announces expansion of product pipeline with HS1940
3/4/2025 - The Fly
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
3/4/2025 - Accesswire
Tharimmune (NASDAQ:THAR) Stock Price Up 3% - Should You Buy?
2/7/2025 - Ticker Report
Tharimmune to Present at the Microcap Conference 2025
1/27/2025 - GuruFocus
Tharimmune to Present at the Microcap Conference 2025
1/27/2025 - Accesswire
Tharimmune files to sell 1.44M shares of common stock for holders
12/19/2024 - The Fly
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus ...
12/16/2024 - GuruFocus
Tharimmune provides business update, corporate highlights
12/16/2024 - The Fly
Tharimmune announces Phase 2 study plan for TH104
12/16/2024 - The Fly
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
12/16/2024 - Accesswire
Tharimmune (NASDAQ:THAR) Research Coverage Started at Rodman and#038; Renshaw
12/9/2024 - Ticker Report
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
12/7/2024 - GuruFocus
Tharimmune announces $2.02M private placement; shares up
12/6/2024 - Seeking Alpha - Healthcare
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$12.43M
Net Income (TTM)
-$12.20M
Balance Sheet
Total Assets (Q)
$3.72M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$2.41M
Book Value Per Share (Q)
$0.6625
Cash Flow
Cash from Operations (TTM)
-$10.90M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$3.53M
Net Change in Cash (TTM)
-$7.38M
Filings
Filing Date
Wednesday, March 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.51
7-Day Total Return
-13.60%
30-Day Total Return
-30.47%
60-Day Total Return
-45.85%
90-Day Total Return
-54.10%
Year to Date Total Return
-42.68%
1-Year Total Return
-82.44%
2-Year Total Return
-99.61%
3-Year Total Return
-99.77%
5-Year Total Return
--
52-week Low
Apr 03, 2025 - $1.14
52-week High
Apr 05, 2024 - $6.98
Valuation
Market Cap
$2.48M - Nano Cap
Enterprise Value
-$1.08M
Price/Sales (TTM)
--
Price/Book (Q)
1.77
Dividends and Shares
Shares Outstanding
1.79M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tharimmune.com
Phone Number
908 955 3140
Address
1200 Route 22 East
Bridgewater, NJ 08807
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical... more
NASDAQ 04/04/2025 3:43PM Eastern Quotes delayed
Weiss Ratings